-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Fosun Pharmaceuticals was authorized by BioNTech SE ("BioNTech") in Germany in March 2020 to develop and commercialize vaccine products based on its proprietary mRNA technology platform, developed exclusively within the region (i.e., Chinese mainland and Hong Kong, Macao and Taiwan, the same below), for the vaccine for new coronaviruses.
the vaccine is a biological product for prevention and is intended to be used mainly for the prevention of new coronaviruses in people aged 18 and over.
as of the date of this announcement, the vaccine is in Phase I clinical trials in Germany and the United States, respectively, and no preventive vaccine developed on the mRNA technology platform has been approved for market worldwide.
as of June 2020, the Group (i.e., the Company and its controlling subsidiaries/units) has invested approximately RMB14.06 million (unaudited; including licensing fees) in research and development of the vaccine at this stage.
.